Clinical trials: Computed Tomography
Cardiovascular Diseases
Study of Management Alterations Resulting From CaRi-Heart® Technology in Patients Undergoing Coronary Computed Tomography Angiography (CCTA) for the Evaluation of Coronary Artery Disease: A United States Based Multi-Centre Study (SMART-CCTA-1)
This study is an assessment of the impact of CaRi-Heart® on the clinical management of patients across at least three centres in the USA.
- Trial name
- SMART-CCTA-1 (NCT06986733)
- Volunteers
- 300 people
- Sponsor
- Caristo Diagnostics Limited
Tibial Fracture
Assessment of the Verus Frame in Tibial Intramedullary Nailing
This prospective, single-arm Post-Market Clinical Follow-Up (PMCF) study, utilizing a registry-based control group, will assess the Verus frame's effectiveness in achieving precise tibial rotation and alignment during…
- Trial name
- NCT07362121
- Testing
- Verus frame to stabilize tibia
- Where
- Finland
- Volunteers
- 25 people
- Sponsor
- Hemitec Finland Oy
Coronary Artery Disease
Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for single-photon…
- Trial name
- NCT00156793
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Acusphere
Performance and Safety
Clinical Study of CT 5400 RT for System Validation
The purpose of this clinical trial is to evaluate the efficacy and safety of the CT 5400 RT System.
- Trial name
- NCT06466577
- Testing
- CT 5400 RT System
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Non-Small Cell Lung Cancer
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed…
- Trial name
- NCT01817192
- Testing
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Where
- 49 sites in United States, France and 1 more
- Volunteers
- 420 people
- Sponsor
- Razor Genomics
Coronary Artery Disease
A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
The purpose of this study is to determine how well perfusion cardiac magnetic resonance (MR) imaging is able to detect certain heart abnormalities, such as a coronary artery narrowing.
- Trial name
- MR-IMPACT-II (NCT00977093)
- Testing
- Perfusion CMR for detection of coronary artery disease, Perfusion cardiac magnetic resonance imaging
- Volunteers
- 533 people
- Sponsor
- Amersham Buchler, GmbH & Co KG
Other Conditions That May Be A Focus of Clinical Attention
Applications of Dual-Energy Computed Tomography
The purpose of the study is to evaluate the feasibility of multilayer detection-based dual energy computed tomography scanner and to assess the added diagnostic value of dual energy applications
- Trial name
- NCT01801514
- Testing
- Computed Tomography scan
- Where
- Israel
- Volunteers
- 337 people
- Sponsor
- Philips Healthcare
Lung Cancer
Clinical Validation of InferRead Lung CT.AI
Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the diagnosis and treatment of…
- Trial name
- NCT04119960
- Testing
- Aided read with InferRead Lung CT.AI
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Infervision
Biopsy or Ablation Procedures
Electromagnetic Tracking of Devices During Interventional Procedures
This prospective, randomized, controlled, parallel-design trial will compare the use of electromagnetic tracking and image guidance during biopsy/ablation procedures verses the typical standard or conventional image guided…
- Trial name
- NCT01279148
- Where
- United States
- Sponsor
- Philips Healthcare
Head and Neck Cancer, Thoracic Cancer
Evaluation of On-Couch CBCT Image Quality
This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology (HyperSight) in patients receiving…
- Conditions
- Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
- Trial name
- NCT06576908
- Testing
- HyperSight Imaging
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Varian, a Siemens Healthineers Company
Hepatocellular Carcinoma
Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma
Most hepatocellular carcinoma (HCC) cases were at advanced stage when diagnosis established. This study is intended to establish a clinical diagnostic model GAMAD for early-stage HCC and evaluate the diagnostic efficiency the…
- Trial name
- NCT05626985
- Testing
- GAMAD
- Where
- 3 sites in China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Fracture Healing, Tibial Fractures
Smart Crutch Tips for Guided Weight-Bearing in Patients Recovering From Tibial Shaft Fractures
The goal of this clinical trial is to learn whether personalized weight-bearing prescriptions using Smart Crutch Tips™ can improve recovery after surgery for tibial shaft fractures.
- Trial name
- NCT07092579
- Testing
- Smart Crutch Tips™, Finite Element Analysis (FEA), Iterative walking
- Where
- 18 sites in Ukraine
- Volunteers
- 30 people
- Sponsor
- Comeback Mobility Inc
Gout
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
The purpose of this study is to evaluate the effect of a high zone tolerizing regimen of pegloticase on clinical outcome, as defined by an serum uric acid level <6 mg/dL, in patients with chronic, refractory gout.
- Trial name
- TRIPLE (NCT02598596)
- Testing
- Pegloticase, Azathioprine
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Ampel BioSolutions, LLC
CT Scanning Patients
Observational Study to Assess the Safety of Omnipure® Inj.(Iohexol) Contrast Media in CT Scanning Patients
The purpose of this study is to assess safety of Omnipure inj. (lohexol) contrast media in CT scanning patients
- Trial name
- NCT02946450
- Testing
- Other: Not applicable-observational study
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Abdominal Aortic Aneurysm
Nectero EAST System Clinical Study
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment.
- Trial name
- stAAAble (NCT06001918)
- Testing
- Nectero EAST System
- Where
- 42 sites in United States, Australia and 1 more
- Volunteers
- 400 people
- Sponsor
- Nectero Medical, Inc.
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Diagnostic Accuracy Of Seismocardiography for Coronary Artery Disease
This study aims to evaluate a new, non-invasive method for detecting coronary artery disease (CAD) using seismocardiography (SCG) and gyrocardiography (GCG).
- Trial name
- HF-CAD (NCT06880120)
- Testing
- Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing
- Where
- Uzbekistan
- Volunteers
- 1,534 people, healthy volunteers welcome
- Sponsor
- Heart Force Medical Inc.
Squamous Cell Carcinoma of the Head and Neck
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This is a single-center cross-sectional imaging and correlative biomarker study in patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN).
- Trial name
- NCT03129061
- Testing
- [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CellSight Technologies, Inc.